Last reviewed · How we verify
Hydrocortancyl.
Hydrocortancyl is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors.
Hydrocortancyl is a corticosteroid that suppresses immune and inflammatory responses by binding to glucocorticoid receptors. Used for Inflammatory and autoimmune disorders (specific indication under investigation in phase 3).
At a glance
| Generic name | Hydrocortancyl. |
|---|---|
| Sponsor | University Hospital, Montpellier |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As a synthetic corticosteroid, hydrocortancyl acts as a glucocorticoid receptor agonist, reducing the production of pro-inflammatory cytokines and inhibiting immune cell activation and migration. This mechanism makes it useful for treating inflammatory and autoimmune conditions where excessive immune activity causes tissue damage.
Approved indications
- Inflammatory and autoimmune disorders (specific indication under investigation in phase 3)
Common side effects
- Immunosuppression
- Hyperglycemia
- Hypertension
- Osteoporosis
- Adrenal suppression
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Loteprednol Etabonate Versus Prednisolone Acetate for Anterior Chamber Granulomas (PHASE4)
- Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
- Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hydrocortancyl. CI brief — competitive landscape report
- Hydrocortancyl. updates RSS · CI watch RSS
- University Hospital, Montpellier portfolio CI